Governance

The International Clinical Trial Center Network (ICN) is led by a Steering Board consisting of representatives of all ten core members. The Steering Board is the responsible, decision-making body of the ICN. Important functions of the Steering Board are to define and manage principles, rules, strategy and operations. The Steering Board also decides on memberships and services offered.
The chairperson of the Steering Board is elected for a period of two years. The current chairperson is Prof. Dr. Yağız Üresin of the Center of Excellence for Clinical Research, Istanbul University.


Steering Board:

J. Spencer Goldsmith (MBA): President, Baim Institute for Clinical Research, Boston, USA

Prof. Dr. Ian Wilkinson: Director of the Cambridge Clinical Trial Unit, Cambridge University Hospitals NHS Foundation Trust, United Kingdom

Rainer Bredenkamp: Director of Clinical Trials Unit Freiburg, Albert-Ludwigs-University of Freiburg, Germany

Henry Yau, (MBA): Managing Director of Clinical Trials Centre, The Hong Kong University, China

Prof. Dr. Yagiz Üresin: Vice Director of the Center of Excellence for Clinical Research, Istanbul University, Turkey

Prof. Dr. Muneo Takatani: Head of Department R&D Alliances, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Japan

Dr. med. Christiane Blankenstein: Director of Münchner Studienzentrum, Hospital rechts der Isar, Technical University of Munich, Germany

Prof. Dr. Rongxing Gan: President and CEO of Shanghai Clinical Research Center, China

Damien Hong, Chief Operating Officer of Singapore Clinical Research Institute, Singapore

Prof. Dr. med. Gabriela Senti, Head of Clinical Trials Center Zurich, University Hospital Zurich, Switzerland

Organization

The ICN operates as much as possible on a decentralized basis. A core team manages common operations and processes.